Florida biotechnology CDMO adding commercial production

Goodwin Biotechnology will build a 40,000-square-foot facility to handle commercial-scale projects. (Goodwin Biotechnology)

After specializing for decades in the production of clinical supplies for biopharma clients, a Florida CDMO has decided it is time to move its services up a notch.

Goodwin Biotechnology said last week it will build a 40,000-square-foot facility next to its existing operations in Fort Lauderdale, doubling its space to take on bigger production projects. The company declined to say what it will invest in the expansion.

“Based on the success of biopharmaceutical candidates that we have helped successfully navigate through their early- and late-stage clinical trials, we have strategically aligned ourselves to invest in doubling our cGMP manufacturing capacity and enhancing our regulatory compliance to support commercial manufacturing,” CEO Karl Pinto said (PDF) in a statement.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The company has traditionally produced monoclonal antibodies, recombinant proteins, vaccines, and biologic drug conjugates including antibody drug conjugates for early- and late-stage clinical trials. But it has been adding capabilities so that it can move to commercial scale projects. Goodwin has already increased its process development capabilities, more than doubling its development bioreactor laboratory. It also has expanded its purification and bioconjugation development and other operations.

The move to commercial production scale comes as a large number of new drugs requires biopharma capabilities but often target small patient populations. The new facility will allow Goodwin to do small- to mid-volume commercial production runs, “which we increasingly see as the future of biopharmaceutical manufacturing,” Pinto said.

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.